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Pioglitazone increases renal tubular cell albumin uptake but
limits proinflammatory and fibrotic responses.
Background. Peroxisome proliferator-activated receptor
gamma (PPARc) agonists, which are known to be critical fac-
tors in lipid metabolism, have also been reported to reduce
proteinuria. The mechanism and its relevance to progressive
nephropathy have not been determined. The aims of this study
were to assess the direct effects of a PPARc agonist on tubular
cell albumin uptake, proinflammatory and profibrotic markers
of renal pathology, using an opossum kidney model of proximal
tubular cells.
Methods. Cells were exposed to pioglitazone (10 lmol/L) in
the presence and absence of low-density lipoprotein (LDL) 100
lg/mL ± exposure to albumin 1 mg/mL. Results were expressed
relative to control (5 mmol/L glucose) conditions.
Results. Pioglitazone caused a dose-dependent increase in
tubular cell albumin uptake (P < 0.0001). Despite the increase
in albumin reabsorption, no concurrent increase in inflamma-
tory or profibrotic markers were observed. Exposure to LDL
increased monocyte chemoattractant protein-1 (MCP-1) (P <
0.05) and transforming growth factor-b1 (TGF-b1) (P < 0.05)
production, which were reversed in the presence of piogli-
tazone. LDL induced increases in MCP-1 and TGF-b1 were
independent of nuclear factor-jB (NF-jB) transcriptional ac-
tivity. In contrast, tubular exposure to albumin increased tubu-
lar protein uptake, in parallel with an increase in MCP-1 (P =
0.05), TGF-b1 (P < 0.02) and NF-jB transcriptional activity
(P < 0.05), which were unaffected by concurrent exposure to
pioglitazone.
Conclusion. These findings suggest that dyslipidemia potenti-
ates renal pathology through mechanisms that may be modified
by PPARc activation independent of NF-jB transcriptional ac-
tivity. In contrast, tubular exposure to protein induces renal
damage through NF-jB–dependent mechanisms that are unaf-
fected by PPARc activation.
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Proteinuria is predictive of progressive deterioration
in renal function in patients with various forms of renal
disease, including diabetes mellitus and primary glomeru-
lar pathology [1–5]. The proinflammatory and profibrotic
effects of albumin on the proximal tubular cell are well
recognized [6, 7]. More recently, the presence of lipid
abnormalities, including elevated levels of native low-
density lipoproteins (LDL), have been implicated both
in the accelerated decline in renal function and in the in-
creased vascular complications observed in patients with
renal disease [8, 9]. Peroxisome proliferator-activated re-
ceptors (PPARs) are members of the nuclear hormone
receptor superfamily of ligand-dependent transcription
factors and have been shown to be critical factors in lipid
metabolism [10]. It is clear that the thiazolodinedione
PPAR gamma (PPARc) ligands additionally reduce al-
buminuria in both humans with type II diabetes mel-
litus and in animal models [11–13], but the relevance
of this to progressive renal disease has not been deter-
mined. In particular, the effect of stimulating PPARc
activity on objective markers of tubulointerstitial renal
disease, which correlate most highly with functional renal
decline, is unknown. PPARc activation has been shown
to modify the proatherogenic cytokine production inher-
ent in atherogenesis, such as enhanced interleukin (IL)-1,
IL-6, and tumor necrosis factor-a (TNF-a) [14, 15], and
glomerular production of transforming growth factor-b1
(TGF-b1) [16, 17], but studies on the effects of PPARc in
the tubulointerstitium are lacking. PPARc agonists have
previously been considered to inhibit the activity of
proinflammatory transcription factors such as nuclear
factor-jB (NF-jB), activating protein-1 (AP-1), and sig-
nal transducer and activator of transcription (STAT) [18].
However, more recently it is recognized that mediators
independent of transcriptional factors such as NF-jB play
a role in the complications of diabetes mellitus, including
nephropathy [19].
Current evidence would suggest that PPARc expres-
sion in the kidney predominates in renal medullary
collecting ducts with lower levels in glomeruli and
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microvasculature [20, 21]. However, the proximal tubule
accounts for 90% of the volume of the kidney, tubu-
lointerstitial disease predicts declining renal function and
thickening of the proximal tubular basement membrane
is the earliest manifestation of nephropathy in patients
with diabetes mellitus. Hence, the current investigation
aimed to assess the direct effects of a PPARc agonist on
tubular cell albumin uptake, proinflammatory and profi-
brotic markers of renal pathology following exposure to
LDL in the presence or absence of albumin.
METHODS
Cell culture
Opossum kidney cells were used as an invitro model
of proximal tubular cells. Cells were routinely grown
in plastic tissue culture flasks (75 cm2) in Dulbecco’s
modified Eagle’s media and Hams F-12 (DMEM/F-12)
(ICN Pharmaceuticals, Inc., Costa Mesa, CA, USA),
supplemented with 10% fetal calf serum (FCS) (Trace
Biochemicals, Sydney, Australia), 2 mmol/L L-glutamine
(catalogue number 17-605E) (Bio-Whittaker, Walk-
ersville, MD, USA), and 50 U/mL penicillin and 50 lg/
mL streptomycin (catalogue number 17-603E) (Bio-
Whittaker). Cells were grown to confluence in a 95%
air-5% CO2 incubator.
Isolation of LDL
LDL was prepared as previously described [22]. Briefly,
whole blood obtained from individual normolipidemic
healthy donors was collected into 50 mL tubes contain-
ing disodium ethylenediaminetetraacetate (EDTA) (200
mmol/L, 0.5 mL), aprotinin (5 to 10 trypsin inhibitory
units, 50 lL (Sigma-Aldrich, St. Louis, MO, USA),
PPACK (1 lmol/L final concentration, D-phenylalanyl-L-
arginine chloromethyl ketone) (Calbiochem, San Diego,
CA, USA) and soybean trypsin inhibitor (0.2 mg/mL final
concentration) (Sigma-Aldrich). Plasma was separated
by centrifugation (3000 rpm (16000g), 20 minutes, 10◦C).
LDL (1.05 > density > 1.02 g/mL) was isolated on a
discontinuous gradient using a Beckman L8-M ultracen-
trifuge (Palo Alto, CA, USA) and a VTi50 rotor (206,000g
(average), 2.5 hours, 10◦C). A second centrifugation at
a density of 1.063 g/mL using a Ti70 rotor (184,000g
(average), 22 hours, 10◦C) removed traces of contam-
inating albumin. The LDL was dialysed against four
exchanges of deaerated Dulbecco’s modified phosphate-
buffered saline (PBS), pH 7.4 (Sigma-Aldrich), contain-
ing chloramphenicol (0.1 g/L) and EDTA (1 g/L), then
filter-sterilized (0.45 lm). LDL was then stored in the
dark at 4◦C and used within 14 days, at which time the
LDL was desalted by passing it through two Sephadex
G-25 M columns (Column PD-10) (Amersham Pharma-
cia Biotech UK, Buckinghamshire, England) using PBS
(treated with Chelex 100 resin) (Bio-Rad, Hercules, CA,
USA) as the buffer. LDL protein concentration was de-
termined using the Bio-Rad Protein Assay.
Experimental protocol
All experiments were carried out on quiescent, con-
fluent opossum kidney cells. Cells were made quiescent
by incubation for 24 hours in control media (DMEM/F-
12 containing 5 mmol/L glucose and antibiotics as above)
without serum. The cells were exposed for 24 hours to me-
dia containing (1) 5 mmol/L D-glucose alone (control) ±
pioglitazone (initial dose finding studies were performed
at concentrations ranging from 0.1 to 10 lmol/L piogli-
tazone and subsequent experiments using pioglitazone
were undertaken using 10 lmol/L pioglitazone as no cy-
totoxicity was demonstrated and growth responses had
plateaued from those observed using 3 lmol/L pioglita-
zone); (2) 100 lg/mL LDL ± 10 lmol/L pioglitazone (this
concentration of LDL was shown in dose-finding studies
to have no cytotoxicity, maximal pathophysiologic effects,
and is a clinically relevant concentration of LDL); (3)
1 mg/mL albumin ± 10 lmol/L pioglitazone (this con-
centration was selected to mimic the concentration of
albumin that the proximal tubule would be exposed to in
proteinuric states); and (4) 1 mg/mL albumin and
100lg/mL LDL ± 10 lmol/L pioglitazone.
After 24 hours, the cells were studied as detailed below.
PPARc expression in opossum kidney cells
PPARc protein expression in opossum kidney cells was
confirmed by Western blot analysis. Cells were lysed in
cell lysis buffer containing 150 mmol/L NaCl, 1 mmol/L
EDTA, 1% Triton X-100, 20 mmol/L Tris, pH 7.5, and
“Complete” protease inhibitor cocktail (Roche Diagnos-
tics, Mannheim, Germany). Triton X-100 soluble frac-
tions were collected following centrifugation of the lysed
cells at 14,000 rpm for 10 minutes. Laemmli buffer was
added and the samples separated by 12% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to nitrocellulose membranes and
then blocked overnight at 4◦C in 5% skim milk in
Tris-buffered saline (TBS)/Tween20 (Sigma Chemical,
St. Louis, MO, USA). The membranes were incubated
with mouse anti-PPARc antibody (1:1000) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at room temper-
ature for 2 hours and after washing with TBS/Tween
20, incubated for a further 60 minutes at room temper-
ature with an antimouse IgG horseradish peroxidase-
conjugated antibody (1:1600) (Amersham Biosciences
UK, Little Chalfont, Buckinghamshire, England). The
antibody used in this study recognizes both PPARc
isoforms 1 and 2. Bound antibodies were detected
using enhanced chemiluminescence (ECL) Western Blot
Kit (Amersham Biosciences UK) and visualized on
chemiluminescence film (Hyperfilm ECL) (Amersham
Pharmacia Biotech UK).
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Assessment of cell growth
Cell counts, as a measure of cell proliferation, were
performed manually on trypsinized cells using a hemo-
cytometer in each of the experimental conditions. The
total protein content of cells was determined as a marker
of cellular hypertrophy. Cells were solubilized with 0.2
mol/L NaOH and the protein measured using a Bio-Rad
protein assay.
Albumin uptake
Cells were grown in 48-well plates to confluence and
were exposed to the experimental conditions outlined
above. The cells were then washed three times with ice-
cold Hepes-Ringer (pH 6.0). After incubation in Hepes-
Ringer (pH 7.4) containing 100 lg/mL Texas Red–labeled
bovine serum albumin (BSA) for 2 hours at 37◦C, un-
bound Texas Red–BSA was removed by rinsing five times
with ice-cold Hepes-Ringer (pH 7.4). Finally, the cells
were lysed using 3[N-morpholino] propane sulfonic acid
(MOPS) solution containing the detergent Triton X-100
(0.1% vol/vol), which ensured that all fluorescence mea-
surements were performed at pH 7.4. The intracellular
fluorescence was measured using a spectrofluorometer
(Fusion, Packard, Perkin Elmer Life Sciences, Boston,
MA, USA) at an excitation wavelength of 580 nm and an
emission wavelength of 630 nm. Cells were solubilized
with 0.2 mol/L NaOH and the protein content measured.
Cytokine production
Active TGF-b1 and monocyte chemoattractant
protein-1 (MCP-1) production were measured on su-
pernatants using commercially prepared enzyme-linked
immunosorbent assay (ELISA) kits (TGF-b1 Emax Im-
munoAssay System) (Promega Corporation, Madison,
WI, USA and BioSource International, CA, USA).
NF-jB specific reporter gene assay
The activation of a NF-jB–specific cis-acting enhancer
element was surveyed in vitro using the Mercury Pathway
Profiling SEAP (secreted alkaline phosphatase) System
(Clontech Laboratories, Inc., Palo Alto, CA, USA). The
SEAP gene served as the target gene. At 24 hours af-
ter plating, the opossum kidney cells were 80% confluent
and they were transiently transfected with the pNF-jB-
SEAP using the Effectene Transfection Reagent (Qia-
gen, GmbH, Hilden, Germany). The transfection reagent
was removed after 8 to 10 hours and fresh growth media
applied. After a further 24 hours, the cells were quiesced
in serum-free medium for 24 hours and then exposed to
the defined experimental conditions for 24 hours. At this
time the supernatants were collected and the cells were
washed with PBS and then solubilized with 0.2 mol/L
NaOH for determination of total protein.
50 kD
Fig. 1. Peroxisome proliferator-activated receptor gamma (PPARc) is
expressed in opossum kidney cells. Western Blot of opossum kidney
cell lysate showing that PPARc is expressed in opossum kidney cells
and has a molecular weight of ∼50 kD.
NF-jB–dependent SEAP reporter protein expression
was measured in serum-free culture medium samples
(1:4 diluted with SEAP buffer) after heat inactivation
of endogenous alkaline phosphatase (incubation at 65◦C
for 30 minutes) using disodium 3-(4-methoxyspiro{1,
2-dioxetane-3, 2′-(5′-chloro)tricyclo[3, 3, 1, 13,7] decan}-
4-yl) phenyl phosphate (CSPD) Substrate (Applied
Biosystems, Bedford, MA, USA) as a chemilumines-
cent substrate for SEAP and measuring the peak
light emission using a luminometer (Fusion, Packard,
Perkin-Elmer Life Sciences). Results were corrected for
cell protein.
Statistical analysis
All experimental conditions were replicated three to
eight times. All results are expressed as a percentage of
the control value (100%). Results are expressed as mean
± SEM. Statistical comparisons between groups were
made by analysis of variance (ANOVA) unless otherwise
stated. Pairwise multiple comparisons were made by the
Fisher protected least-significant differences test. Analy-
ses were performed using the software package, StatView,
version 5.01 (Abacus Concepts, Inc., Berkley, CA, USA).
P values less than 0.05 were considered significant.
RESULTS
Detection of PPARc in opossum kidney cells
Western blotting demonstrated a single band of molec-
ular weight ∼50 kD indicating that PPARc1 is the pre-
dominant isoform in these cells (Fig. 1).
Cell growth (cell number and cell protein)
Hypertrophy was induced by exposure to LDL (114 ±
3%; P < 0.0001), albumin (127 ± 2%; P < 0.0001),
and pioglitazone (119 ± 3%; P < 0.0001). Pioglitazone
did not modify the hypertrophic effect of LDL or albu-
min. No treatment altered the cell proliferative response
(Fig. 2).
Albumin uptake
Exposure of opossum kidney cells to pioglitazone re-
sulted in a dose-dependent increase in albumin uptake,
which was maximal at a concentration of 10 lmol/L, being
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Fig. 2. Growth in opossum kidney cells ex-
posed to pioglitazone with and without low-
density lipoprotein (LDL) and/or albumin.
Cell protein (A) and cell number (B) in opos-
sum kidney cells exposed to the defined treat-
ments for 24 hours. Symbols are: () 5 mmol/L
glucose (5Glc); ( ) 5 mmol/L glucose with
pioglitazone 10 lmol/L; LDL 100, LDL 100
lg/mL; albumin, albumin 1 mg/mL; LDL +
Alb, LDL 100 lg/mL + albumin 1 mg/mL.
128 ± 5% of control values (P < 0.0001) (Fig. 3A). Hence
this concentration was used in subsequent experiments.
Exposure to LDL reduced albumin uptake to 78 ± 5%
of control values (P < 0.0001) (Fig. 3B), in the absence
of any observed cytotoxicity (data not shown), which
was not modified in the presence of pioglitazone. Albu-
min uptake was stimulated by prior exposure to albumin
to 116 ± 7% of control (P = 0.05), which was further
enhanced in the concurrent presence of pioglitazone to
159 ± 12% of control values (P < 0.0001). Exposure to
the combination of LDL and albumin did not alter tubu-
lar albumin uptake, and the addition of pioglitazone to
the combination of LDL and albumin, had no observed
effect.
TgF-b1 production
Pioglitazone 10 lmol/L alone had no significant ef-
fect on TGF-b1 production. Exposure of opossum kid-
ney cells to LDL caused a significant increase in TGF-b1
production (140 ± 15%; P < 0.05). Pioglitazone reversed
this effect (Fig. 4). Exposure to albumin also stimulated
TGF-b1 production (126 ± 11%; P < 0.02). However,
concurrent exposure to pioglitazone did not modify this
response. The combination of LDL and albumin did not
alter TGF-b1 production.
MCP-1 production
Pioglitazone 10 lmol/L alone had no significant effect
on MCP-1 production. Exposure of opossum kidney cells
to LDL 100 lg/mL caused a significant increase in MCP-1
production (185 ± 23%; P < 0.05), which was reversed
with the addition of pioglitazone 10 lmol/L (Fig. 5). Al-
bumin resulted in a significant increase in MCP-1 (289 ±
116%; P = 0.05), which was not reversed by pioglita-
zone. The combination of LDL and albumin did not alter
MCP-1 production.
NF-jB reporter gene assay
Pioglitazone 10 lmol/L alone had no significant ef-
fect on NF-jB promoter activity. Exposure of opossum
kidney cells to LDL 100 lg/mL in the absence or pres-
ence of albumin caused a significant decrease in NF-jB
promoter activity (74 ± 3%; P < 0.01, and 76 ± 2%;
P < 0.01 respectively). The addition of pioglitazone to
LDL ± albumin did not modify this response (Fig. 6).
Albumin exposure to opossum kidney cells stimulated
NF-jB activity (123 ± 6%; P < 0.05) and this was not
altered in the presence of pioglitazone.
DISCUSSION
In the present study we have confirmed the presence
of the PPARc isoform c1 in the opossum kidney proxi-
mal tubule model. PPARc2 is known to primarily occur in
adipose tissue and PPARc1 more ubiquitously expressed.
However, in the kidney it has largely been previously
described in the distal tubule of the kidney, with lesser ex-
pression in the vasculature and glomeruli [21]. The find-
ing that PPARc was expressed in the proximal tubule,
which forms the bulk of the renal mass and is specifically
implicated in the tubulointerstitial response to renal in-
jury, characteristic of progressive nephropathy, suggested
that the role of PPARc agonists in proximal tubular cell
models should be further explored.
The present study has demonstrated that the reduc-
tion in proteinuria observed following treatment with
PPARc agonists is at least partly explained by increased
tubular cell albumin uptake. Of concern is that increased
“protein trafficking” may have potential deleterious con-
sequences. MCP-1 and additional cytokines such as
IL-8 have been previously implicated in the proinflam-
matory consequence of enhanced tubular albumin up-
take [23–25]. Our experiments clearly demonstrate that
enhanced tubular uptake of albumin induced by prior
exposure of cells to albumin results in increased pro-
duction of the proinflammatory cytokine MCP-1 and the
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Fig. 3. Albumin uptake in opossum kidney cells. (A) Following 24
hours’ exposure to different concentrations of pioglitazone (0.1 to 10
lmol/L), opossum kidney cells were incubated with Texas Red–bovine
serum albumin (BSA) (100 lg/mL) for 2 hours, after which time the in-
tracellular Texas Red–BSA uptake was measured and corrected for cell
protein. Results are standardized against control conditions (opossum
kidney cells in 5 mmol/L glucose). (B) Albumin uptake in opossum kid-
ney cells exposed to pioglitazone with and without low-density lipopro-
tein (LDL) and/or albumin. Following 24 hours’ exposure to the defined
treatments, opossum kidney cells were incubated with Texas Red–BSA
(100 lg/mL) for 2 hours, after which time the intracellular Texas Red–
BSA uptake was measured and corrected for cell protein. Symbols are:
() 5 mmol/L glucose (5Glc); ( ) 5 mmol/L glucose with pioglitazone 10
lmol/L; LDL 100, LDL 100 lg/mL; albumin, albumin 1 mg/mL; LDL
+ Alb, LDL 100 lg/mL + albumin 1 mg/mL.
profibrotic cytokine TGF-b1. In contrast, the enhanced
albumin uptake induced by pioglitazone was not asso-
ciated with an increased inflammatory or profibrotic cy-
tokine response. Hence, proteinuria is reduced without
potential deleterious effects on the tubulointerstitium.
We have recently demonstrated that tubular albumin
uptake is associated with increased activity of the sodium-
hydrogen exchanger [26], responsible for sodium reab-
sorption in the proximal tubule. Although not addressed
in the present study, it is interesting to speculate that the
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Fig. 4. Transforming growth factor-b1 (TGF-b1) secretion in opos-
sum kidney cells exposed to pioglitazone with and without low-density
lipoprotein (LDL) and/or albumin. Active TGF-b1 levels were mea-
sured by enzyme-linked immunosorbent assay (ELISA) in media con-
ditioned by opossum kidney cells exposed to the defined experimental
treatments for 24 hours. Symbols are: () 5 mmol/L glucose (5Glc);
( ) 5 mmol/L glucose with pioglitazone 10 lmol/L; LDL 100, LDL 100
lg/mL; albumin, albumin 1 mg/mL; LDL + Alb, LDL 100 lg/mL +
albumin 1 mg/mL. #P < 0.05 for LDL 100 lg/mL vs. LDL 100 lg/mL
with pioglitazone 10 lmol/L.
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Fig. 5. Monocyte chemoattractant protein-1 (MCP-1) secretion in
opossum kidney cells exposed to pioglitazone with and without low-
density lipoprotein (LDL) and/or albumin. MCP-1 levels were mea-
sured by enzyme-linked immunosorbent assay (ELISA) in media
conditioned by opossum kidney cells exposed to the defined experi-
mental treatments for 24 hours. Symbols are: () 5 mmol/L glucose
(5Glc); ( ) 5 mmol/L glucose with pioglitazone 10 lmol/L; LDL 100,
LDL 100 lg/mL; albumin, albumin 1 mg/mL; LDL + Alb, LDL 100
lg/mL + albumin 1 mg/mL. #P < 0.05 for LDL 100 lg/mL vs. LDL 100
lg/mL with pioglitazone 10 lmol/L.
edema observed with the thiazolidinediones [27] is due
to enhanced tubular sodium reabsorption inherent in the
increase in tubular albumin uptake.
The presence of lipid abnormalities, including elevated
levels of native LDL, have been implicated in an accel-
erated decline in renal function [8], which is supported
mechanistically by the findings of the present study. As
PPAR agonists have been shown to be critical factors in
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Fig. 6. Nuclear factor-jB (NFjB)-secreted alkaline phosphatase
(SEAP) activity in opossum kidney cells exposed to pioglitazone with
and without low-density lipoprotein (LDL) and/or albumin. NF-jB–
specific reporter gene assay. SEAP expression of opossum kidney
cells exposed to the defined treatments for 24 hours. Symbols are:
() 5 mmol/L glucose (5Glc); ( ) 5 mmol/L glucose with pioglitazone
10 lmol/L; LDL 100, LDL 100 lg/mL; albumin, albumin 1 mg/mL; LDL
+ Alb, LDL 100 lg/mL + albumin 1 mg/mL.
lipid metabolism, we addressed the effect of pioglitazone
on the tubular cell responses to LDL. Our results confirm
that dyslipidemia may be a key factor in the develop-
ment of progressive renal disease. Specifically, exposure
of opossum kidney cells to LDL increased MCP-1 and
TGF-b1 production, which were reversed in the presence
of pioglitazone. Recently, it has been shown in renal and
nonrenal tissue that PPARc agonists increase cholesterol
efflux from cells due to induction of the cholesterol ef-
flux pump ABC-A1 [28]. Reduced cellular accumulation
of cholesterol may therefore be a mechanism whereby
the specific deleterious effects of LDL are ameliorated in
the kidney. Interestingly, despite the independent dele-
terious effects of LDL and albumin on the tubular cells,
the present study did not demonstrate that the combina-
tion of LDL and albumin induced any change in cytokine
release. It is likely that the lipid associated with albumin
and was therefore not taken up into the tubular cells to in-
duce pathology. Clearly, the concurrent exposure of albu-
min and LDL reduced albumin uptake and hence tubular
pathology. However, the mechanism whereby this occurs
is not known.
Although PPARc agonist activity has been previously
attributed to inhibition of the action of nuclear transcrip-
tion factor NF-jB, STAT and AP-1 have also been im-
plicated [14, 15, 29]. Our results suggest that in contrast
to the induction of NF-jB transcriptional activity by ex-
posure to albumin, LDL induced increases in MCP-1
and TGF-b1 were independent of NF-jB transcriptional
activity. Indeed, the proinflammatory and profibrotic
responses induced by exposure to albumin were not mod-
ified by concurrent exposure to pioglitazone, suggesting
that pioglitazone is acting through pathways other than
NF-jB.
The transcriptional regulation of MCP-1 has previously
been attributed, at least in part to NF-jB dependent path-
ways [24]. However, the promoter regions that control
MCP-1 gene expression are variable and suggest exten-
sive interactions between both transcription factors and
promoter elements [30]. The murine MCP-1 promoter
contains AP-1 and specificity protein-1 (SP-1), in addi-
tion to NF-jB promoter sites, hypermethylation and or-
phan sites, all of which regulate MCP-1 activity [30]. In the
opossum kidney cell model and in humans, the signaling
pathways that govern MCP-1 expression are not known.
NF-jB–independent pathways have been observed in
adipocytes where the thiazolidinedione, troglitazone, was
shown to have no effect on NF-jB activation and DNA
binding activity in response to TNF-a. Clearly, modifica-
tion of NF-jB by factors such as IjB-a may still mediate
an effect of NF-jB independent of transcriptional activ-
ity. However, to date this has not been addressed. The
reduction in TGF-b1 secretion induced by pioglitazone
in the presence of LDL suggests that the profibrotic ef-
fects of LDL may also be abrogated by PPARc agonists.
As TGF-b1 is regulated through an AP-1 promoter this
also suggests that pioglitazone is acting through NF-jB–
independent mechanisms. TGF-b1 is clearly implicated
in all forms of progressive renal disease. Hence, its mod-
ification is of key therapeutic significance.
CONCLUSION
We have demonstrated the key role that elevated LDL
levels may play in the development of tubular pathology
characteristic of progressive renal disease. Tubular dys-
function mediated by exposure to LDL occurs in asso-
ciation with increased secretion of the proinflammatory
and profibrotic cytokines MCP-1 and TGF-b1, which are
normalized in the presence of the PPARc agonist piogli-
tazone. Our findings suggest that dyslipidemia potenti-
ates renal pathology through mechanisms independent
of NF-jB transcriptional activity. In contrast, tubular ex-
posure to protein induces renal damage through NF-jB–
dependent mechanisms that are unaffected by PPARc
activation. These findings suggest that PPARc agonist
therapy in patients with metabolic characteristics inher-
ent in renal disease may reduce proteinuria and poten-
tially delay progression of tubulointerstitial disease by
reducing the inflammatory and fibrotic response.
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